Halting the Epidemic of Addiction and Loss Act of 2025

S. 2336 would require the Department of Health and Human Services to update regulations and grant program guidance to include any FDA-approved opioid overdose reversal drug, not just naloxone. The bill would affect two major grant programs: State and Tribal Opioid Response Grants and grants for priority substance use disorder prevention needs. Within one year of enactment, the HHS Secretary would need to update existing references in these programs to recognize all federally approved overdose reversal medications.

The bill aims to ensure that federal grant programs remain flexible and can incorporate emerging medical treatments as they become available. By broadening the types of overdose reversal drugs that can be used in federally funded programs, the legislation seeks to provide communities with more options for saving lives during opioid overdoses. This would allow states and tribes to use newer or alternative overdose reversal agents alongside naloxone, potentially improving outcomes in the ongoing opioid crisis.